How has been the historical performance of Trident Texofab?

Answer:The historical performance of Trident Texofab shows a steady growth in net sales and profitability over the years, with significant fluctuations in costs and expenses.

Breakdown:
Trident Texofab's net sales have increased from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25, reflecting a strong upward trend. The total operating income has similarly risen, reaching 122.06 Cr in Mar'25 from 96.36 Cr in Mar'23. Raw material costs peaked at 23.58 Cr in Mar'23 but have since decreased to 18.68 Cr in Mar'25, while the purchase of finished goods has grown significantly from 34.09 Cr in Mar'21 to 89.02 Cr in Mar'25. Operating profit, excluding other income, was 5.48 Cr in Mar'25, down from 6.31 Cr in Mar'23, indicating some pressure on margins. Profit before tax has shown variability, with a notable increase to 2.58 Cr in Mar'25 from 1.17 Cr in Mar'24. The profit after tax also rose to 2.51 Cr in Mar'25 from 1.08 Cr in Mar'24. The company's total assets increased to 100.58 Cr in Mar'25 from 81.90 Cr in Mar'24, while total liabilities also grew to 100.58 Cr in Mar'25 from 81.90 Cr in Mar'24. Cash flow from operating activities turned negative at -13.00 Cr in Mar'25, contrasting with a positive cash flow of 2.00 Cr in Mar'24, although cash and cash equivalents improved to 3.00 Cr in Mar'25 from 0.00 Cr in Mar'24. Overall, Trident Texofab has demonstrated growth in sales and profitability, despite challenges in operating margins and cash flow management.